Enkephalin Degrading Enzymes: Metalloproteases with High Potential for Drug Development

E-ISSN： 1873-4286|18|2|220-230

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.2, 2012-01, pp. : 220-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of imipramine on enkephalin-degrading peptidases

By de Gandarias J.M. Irazusta J. Varona A. Gil J. Fernandez D. Casis L.

European Neuropsychopharmacology, Vol. 9, Iss. 6, 1999-12 ,pp. : 493-499

Elsevier

Access to resources Recommend Favorite

Enzymes of the Trypanothione Metabolism as Targets for Antitrypanosomal Drug Development

Current Topics in Medicinal Chemistry, Vol. 2, Iss. 11, 2002-11 ,pp. : 1239-1259

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Schistosome Histone Modifying Enzymes for Drug Development

Current Pharmaceutical Design, Vol. 18, Iss. 24, 2012-08 ,pp. : 3567-3578

Bentham Science Publishers

Access to resources Recommend Favorite

Matrix metalloproteases: Underutilized targets for drug delivery

By Vartak Deepali Gemeinhart Richard

Journal of Drug Targeting, Vol. 15, Iss. 1, 2007-01 ,pp. : 1-20

Informa Healthcare

Access to resources Recommend Favorite

Imipramine inhibits soluble enkephalin-degrading aminopeptidase activity in vitro

By Gallego M. Casis L. Casis O.

European Journal of Pharmacology, Vol. 360, Iss. 1, 1998-10 ,pp. : 113-116

Elsevier

Access to resources Recommend Favorite